Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

Exclusion Criteria

• •History of glaucoma in the study eye with intraocular pressure \>21mmHg on more than one topical medication. Combination drugs are considered more than one medication
• •History of steroid-related glaucoma (steroid response)
• •Previous intraocular injection of steroid medication within 90 days
• •Avastin (bevacizumab) or Lucentis (ranibizumab) within 60 days
• •Evidence of significant retinal ischemia on fluorescein angiography in the opinion of the treating physician
• •Previous intraocular surgery (e.g. Cataract Surgery) with in 60 days
• •Concurrent ocular disease that would limit visual acuity in the opinion of the treating physician
• •Dense cataract that precludes clinical examination and retinal imaging of the retina
• •History of allergy to dexamethasone, bevacizumab, betadine
• •Ocular or systemic conditions that may pose a threat to the health of the subject in the opinion of the treating physician
• •Unwilling or unable to follow or comply with all study related procedures
• •Current participation in another clinical medical investigation or trial or has received any investigational drug within 12 weeks prior to enrollment